These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25416646)

  • 1. PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2015 Feb; 25(2):175-91. PubMed ID: 25416646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amorfrutins are efficient modulators of peroxisome proliferator-activated receptor gamma (PPARγ) with potent antidiabetic and anticancer properties: a patent evaluation of WO2014177593 A1.
    Lavecchia A; Di Giovanni C
    Expert Opin Ther Pat; 2015; 25(11):1341-7. PubMed ID: 26536161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).
    Lamers C; Schubert-Zsilavecz M; Merk D
    Expert Opin Ther Pat; 2012 Jul; 22(7):803-41. PubMed ID: 22697317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present).
    Takada I; Makishima M
    Expert Opin Ther Pat; 2020 Jan; 30(1):1-13. PubMed ID: 31825687
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S; Dougherty EJ; Danner RL
    Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
    Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
    Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of thiazolidinediones.
    Tolman KG
    Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone as a target of type 2 diabetes treatment.
    Lecka-Czernik B
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1085-90. PubMed ID: 19777397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico approach for the discovery of new PPARγ modulators among plant-derived polyphenols.
    Encinar JA; Fernández-Ballester G; Galiano-Ibarra V; Micol V
    Drug Des Devel Ther; 2015; 9():5877-95. PubMed ID: 26604687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
    Whitehead JP
    Int J Biochem Cell Biol; 2011 Aug; 43(8):1071-4. PubMed ID: 21558015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
    Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
    Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
    Gelman L; Feige JN; Desvergne B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones and PPARγ agonists: time for a reassessment.
    Cariou B; Charbonnel B; Staels B
    Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT; Sharma AM
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.